construct
move sidelin andexxa headwind
color fundament focu call
oppenheim innov seri new frontier cancer cell
diamond rough initi outperform
posit constant data support best-in-class profil sci-b-
best-in-class compani initi outperform
market leader sleep apnea solut initi perform
analyst certif import disclosur see
rise player aesthet laser dermatolog initi
review valu inflect expect
per share special dividend declar payabl
top-lin downshift persist could facilit comparison time
result bit kitchen sink stock remain excel
construct
reiter outperform adjust ebitda y/i view opportun upsid via
expens manag target potenti profit growth although anticip year solid
adjust ebitda growth/margin expans like last year start blemish-fre otherwis like consist prior
expect recent french labor protest appear increment disrupt decemb busi activ
countri correspondingli modifi y/i adjust ebitda respect
reiter target base conserv sum-of-the-part sotp valuat assess appear
deeply-discount rel key peer repres ev/ebitda adjust ebitda
move sidelin andexxa headwind
announc andexxa revenu expect commentari describ certain headwind includ
drug util review certain hospit temporarili blunt demand slightli lower rate new hospit add
one-tim net sale adjust return short-dat product replac longer-d product
andexxa revenu well estim consensu back reserv short-
date return us revenu would q/q significantli miss estim
consensu updat model reflect latest andexxa dynam result lower revenu ep estim
chang drive new dcf-base pt vs prior reduc rate perform
event year large-cap orthoped name primari focu close
integr wright medic acquisit expect would assum minor divestitur anticip
anoth bidder look solid sale growth growth broad-bas led medsurg
neurotechnolog assum ep growth exclud expect near-term deal dilut bring growth
rate share perform valuat remov price target focu continu
shift growth acceler led new product rollout underappreci opportun believ gross margin
expans impact use cash tuck-in rate outperform new sale drive increas
gm focu trade discount peer pt rise
intuit surgic pre-announc last night true histor trend came better estim revenu
slightli better consensu estim estim recent nois softer
procedur volum intuit turn red her compani continu march push robot surgeri
across board view stock no-man land ye quarterli surpris sure justfi
valuat higher forward p/ forward price-to-earnings
opportun sit cfo colett kress ir vice-president simona jankowski ce week tone
bullish management discuss ai workload opportun within dc ray trace catalyst core game segment
visibl improv dc hyperscal spend re-acceler management see jan dc q/q sale growth
acceler q/q growth oct management attribut new ai demand hyperscal natur
languag process nlp use speech search nlp requir process power vs current workload
boost train infer gpu attach enterpris nlp demand also increas led need improv
call center function management see nlp drive next leg dc ai growth move holiday
game demand appear solid ray tracingen titl hit critic mass remain well posit capit
opportun dc ai high perform game autonom vehicl top large-cap growth stori
remain buyer
initi dc ai workload train neural network imag process management see nlp next growth wave
hyperscal increasingli focu real-tim convers understanding/product human languag management estim
workload alreadi use nlp inferenc revenu grown lsd dc revenu
roughli year ago run rate volum exceed volum estim
carri asp vs carri above-averag gm
met vice-president ir ashish saran ce week tone meet posit mr saran discuss bt
outlook resurg interest arm thunderx server processor continu ramp shipment lead
custom samsung expect complet purpos built macro bt deploy year util mrvl ecpu baseband
switch phi massiv mimo custom front haul estim mrvl content samsung
deploy underway korea us expect follow baseband shipment nok track begin
ramp estim nok macro bt content recent avera acquisit bring
season team custom asic engin revenu eric long-stand avera dfe custom
make half avera sale view offer industri complet end-end infrastructur
portfolio see increment revenue/ep potenti next year server anoth potenti
sourc upsid like led renew interest arm driven power/cost save desir hyperscal
special workload silicon remain purest stori semi top mid-cap pick
emerg technolog servic
one thing count strong technolog custom want past four year non-
baseband licens deal sign impress highlight compani power posit howev
think addit near-term uncertainti may aris royalti first difficult forecast non-baseband due wide
rang second time bigger opportun like base station remain larg elus third legaci mobil
baseband move signific transit believ present strong headwind
point street well vs
color fundament focu call
oppenheim innov seri new frontier cancer cell therapi
cancer cell therapi offshoot immuno-oncolog patient treat live immun cell leverag
groundbreak academ research field experienc remark progress last decad advanc product
borderlin scienc fiction commerci realiti first commerci t-cell therapi cancer yescarta kymriah
approv product offer lifelin patient intract hematolog malign
space attract area biotech investor thank brisk pace partnership capit influx
believ bulk innov fieldmak cellular therapi better stronger faster broadli applicablei
carri small compani could repres attract opportun risk-toler investor report
overview landscap spotlight innov believ could becom futur star cancer cell therapi
diamond rough initi outperform
initi coverag outperform rate price target continu build
pediatr rare diseas player anticip merger aevi genom medicin gnmx favor view
incom develop asset adult-onset still diseas oppti lymphat malform
oppi may see phase data complement compani intern program ultra-
rare metabol disord oppti potenti approv could gener valuabl saleabl fda
voucher ev suggest share hold sizabl upsid potenti merger close pipelin progress
regist
preliminari revenu y/i handili beat consensu slightli
estim presum nearli figur bivigam sale asceniv new product still earli phase
launch reiter outperform
posit constant data support best-in-class profil sci-b-vac
phase constant trial sci-b-vac adult age design primarili show lot-to-lot consist met
primari secondari endpoint notabl seroprotect follow two dose demonstr non-inferior three
dose engerix-b import patient need rapid seroprotect well poor adher third
best-in-class compani initi outperform
initi coverag outperform rate price target edward contend
strong/strateg manag team best-in-class product minim invas heart valv replac
strong profil ebit margin ep compound-annual-growth-rate revenu annual compound-annual-growth-rate
strong competit posit conduct level studi clear evid improv patient outcom
tavr space worth translat compound-annual-growth-rate next year mitral space proven could
multipl aortic space anyon crack code mitral believ edward
market leader sleep apnea solut initi perform
initi coverag perform rate market continu posit airway pressur cpap
solut obstruct sleep apnea osa condit character upper airway collaps human sleep osa
acut effect includ daytim sleepi fatigu left untreat osa lead chronic effect like hypertens
arrhythmia heart failur etc approxim sleep apnea either undiagnos untreat lead viciou
cause-effect cycl current annual sleep apnea space grow compound-annual-growth-rate
biggest headwind space price eros unleash competit bid contend
continu well manag omnipres headwind
rise player aesthet laser dermatolog initi outperform
initi coverag venu concept emerg player aesthet laser space outperform rate
pt venu recent complet revers merger restor robot creat combin sale footprint
spread across countri provid venu access robot technolog potenti use aesthet dermatolog
fundament posit stanc stori base savvi ceo uniqu subscript model reduc up-front
capit outlay custom improv revenu predict venu introduc customer-sticki factor
venu bliss compani non-invas fat reduct devic could signific growth driver
review valu inflect expect
neubas nbse report result provid busi updat nbse guid report pk pd
data start on-going preclin studi non-human primat nhp huntington diseas
hd myoton dystrophi type look forward system administ molecul potenti
biodistribut data includ blood-brain barrier penetr cell permeabl pk tend come
first follow efficaci data pd upon support preclin poc profil could potenti see
potenti move clinic hd potenti nbse talent experienc manag team
upcom materi catalyst platform valid see year valu inflect updat
model nbse file upcom competitor hc stay bullish
per share special dividend declar payabl
market close declar expect one-tim special cash dividend per share equat
capit return sharehold after-tax proce sale enterpris asset broadcom
close trade higher market main question investor
mind estim valuat remain compani consum busi worth estim
consum busi potenti garner anywher anoth potenti outcom consum
segment could merger stand-alone consum secur compani privat equiti transact schedul
report
opportun sit corpor develop head tom sepenzi week ce tone
meet bullish mr sepenzi highlight opportun infrastructur smartphon view
infrastructur gain momentum ahead schedul two custom one massive-mimo small cell small
cell util filter per bt wherea massive-mimo design use filter per bt
expect infrastructur revenu ramp begin ce announc shipment
tandem coexist filter fifth potenti custom oem see industri first tandem solut well posit
address interfer issu new band design xbaw solv coexist
smaller size incumb dielectr brick reson dr addit announc
complet intern wafer level packag wlp enabl reduc footprint vs current dr filter
singl crystal design enabl improv power handl form factor wlp tabl stake view futur
handset win expect hockey stick growth begin wifi/bts/smartphon design ramp reiter
allow wider signal rang led engag two key equip oem one engag
massive-mimo carri filter per bt target korean market small cell target
region china believ power level beat avgo/qrvo spur engag network
wi-fi penetr boost comet lake notebook digitim
see believ intel teas discret xe gpu laptop desktop dev card ce anand
emerg technolog servic
attend booth tour vice-president investor relat ann nicholson ce compani showcas coldform
technolog alumina ribbon ceram masterpix fine glass print astra glass came away impress
corn continu pursuit process materi innov abil bring invent mass market
especi intrigu alumina ribbon ceram seem substanti applic electron
industri due rise demand high-pow high-frequ devic miniatur
verizon launch mix match plan
industri confer note vz
tweak model vz
infosi report solid result cc y/i revenu growth vs estim
oper margin estim ep compar our/street estim benefit low tax
rate reflect result solid tcv infi rais outlook anticip
cc revenu growth oper margin unchang growth led life scienc
servic retail remain rel soft large-d sign tcv remain solid build
strong trajectori recent quarter faster-grow digit servic repres revenu y/i
notabl infi independ investig conclud whistleblow complaint substanti without merit maintain
top-lin downshift persist could facilit comparison time
revenu continu pattern increment soft sequenti sale advers vs normal season though
rel moder declin sale independ sale network half overal compani declin
contribut improv gm profil continu trend recent quarter larg commerci project remain soft like
weather impact trade matter impact project costs/caus delay potenti improv given
strong custom backlog prospect shift releas new ceo neil ash take rein recent
serv ceo faster hors privat equiti consult follow tenur presid ceo global
e-commerce technolog current ceo vern nagel remain execut chairman success process
expedit neil profile/interest/avail
result bit kitchen sink stock remain excel valu
say sinc initi coverag jefferi asset valu stori earn
progress stori remain convinc stock great valu patient investor reward
handsom said profit flagship invest bank keenli disappoint full-year rotc
fourth quarter bare break-even said sharehold letter manag commit complet
transform jefferi pure financi servic firm conglomer central plan deliv
consist doubl digit return tangibl equiti price target goe primarili increas peer
may biotech summit featur chemistri life process institut chicago il
juli montauk summit emerg life scienc montauk ny
sept fall summit focus specialti pharma diseas gene therapi new york ny
oct houston oncolog summit md anderson cancer center houston tx
